secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001564590-22-037057
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q3 revenue $101.4M, net income $0.09/share; program starts up 33%
---------------------------------------------------------------------------

- Total revenue $101.4M (Q3 2021: $5.5M); net income $26.6M ($0.09 basic EPS) vs net loss $21.4M.
- Bebtelovimab royalties contributed $93.3M; research fees $7.5M, milestones $0.4M, licensing $0.2M.
- Cumulative program starts reached 92, up 33% from 69 in Q3 2021; partners increased to 38.
- Cash, cash equivalents and marketable securities stood at $868M.
- R&D expenses $26.6M (up 52% YoY) reflecting continued investment in discovery engine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022037057/0001564590-22-037057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022037057/abcl-8k_20221108.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-037057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer